New York City, NY -- (SBWIRE) -- 10/04/2013 -- StockMarketIntel.com issues a special report on the following stocks: Galena Biopharma Inc (NASDAQ:GALE), Molycorp Inc (NYSE:MCP), NVIDIA Corporation (NASDAQ:NVDA), Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)
Galena Biopharma Inc (NASDAQ:GALE) was trading lower by -0.10 points or -4.18% to $2.29.So far, around 2.07 million shares have changed hands in this session. After opening at $2.40, the stock hit as high as $2.42. However, it traded between $1.23 and $3 over the last twelve months. Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.
Has GALE Found The Bottom and Ready To Move Up? Find Out Here
Molycorp Inc (NYSE:MCP) was at $7.41, showing a 2.92% increase. Around 3.72 million shares have been traded, versus an-average trading volume of 5.96M shares. The company is now valued at around $1.4 billion. Molycorp, Inc. provides Rare Earths and Molybdenum products to companies. The Company's rare earth products comprise of bastnasite, cerium, europium, lanthanum, neodymium, praseodymium, yttrium, and other lanthanides.
For How Long MCP’s Gloss will Attract Investors? Find out via this report
NVIDIA Corporation (NASDAQ:NVDA) moved 1.43 per cent higher at $15.60 and is trading between $15.32 and $15.65 after opening the day at $15.36. Its performance over the last five days remained -0.32%, which stands at 4.83% for a month. Going back further than one month, 1-year performance after recent close was 29.09%. NVIDIA Corporation (NVIDIA) is engaged in creating the graphics chips used in personal computers (PCs).
Why Should Investors Buy NVDA After the Recent Fall? Just Go Here and
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)’s shares rose today, gaining4.96 per cent to $2.99. The stock is down around -20.02% in 2013 and 20.2% for the last 12 months. Around 1.94 million shares changed hands so far in this session compared to an-average trading volume of 576,069.00 shares. Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic.
Will ONCY Continue To Move Higher? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)